PCI Biotech Holding ASA (OL:PCIB) — Market Cap & Net Worth
Market Cap & Net Worth: PCI Biotech Holding ASA (PCIB)
PCI Biotech Holding ASA (OL:PCIB) has a market capitalization of $274.95K (Nkr2.61 Million) as of May 3, 2026. Listed on the OL stock exchange, this Norway-based company holds position #30732 globally and #273 in its home market, demonstrating a -53.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PCI Biotech Holding ASA's stock price Nkr0.07 by its total outstanding shares 37326390 (37.33 Million). Analyse PCIB cash flow metrics to see how efficiently the company converts income to cash.
PCI Biotech Holding ASA Market Cap History: 2015 to 2026
PCI Biotech Holding ASA's market capitalization history from 2015 to 2026. Data shows change from $10.91 Million to $274.95K (-32.19% CAGR).
PCI Biotech Holding ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PCI Biotech Holding ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.69x
PCI Biotech Holding ASA's market cap is 0.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $10.91 Million | $10.47 Million | -$31.92 Million | 1.04x | N/A |
| 2016 | $54.70 Million | $10.47 Million | -$32.18 Million | 5.22x | N/A |
| 2017 | $153.52 Million | $10.25 Million | -$42.84 Million | 14.98x | N/A |
| 2018 | $103.30 Million | $9.59 Million | -$34.78 Million | 10.78x | N/A |
| 2019 | $301.26 Million | $9.37 Million | -$88.75 Million | 32.15x | N/A |
| 2020 | $109.59 Million | $7.37 Million | -$72.24 Million | 14.87x | N/A |
| 2021 | $54.64 Million | $6.27 Million | -$88.48 Million | 8.71x | N/A |
| 2022 | $8.05 Million | $4.75 Million | -$55.09 Million | 1.70x | N/A |
| 2023 | $8.23 Million | $2.99 Million | -$20.32 Million | 2.75x | N/A |
| 2024 | $4.67 Million | $6.74 Million | -$16.42 Million | 0.69x | N/A |
Competitor Companies of PCIB by Market Capitalization
Companies near PCI Biotech Holding ASA in the global market cap rankings as of May 3, 2026.
Key companies related to PCI Biotech Holding ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PCI Biotech Holding ASA Historical Marketcap From 2015 to 2026
Between 2015 and today, PCI Biotech Holding ASA's market cap moved from $10.91 Million to $ 274.95K, with a yearly change of -32.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr274.95K | -71.54% |
| 2025 | Nkr966.24K | -79.29% |
| 2024 | Nkr4.67 Million | -43.29% |
| 2023 | Nkr8.23 Million | +2.20% |
| 2022 | Nkr8.05 Million | -85.26% |
| 2021 | Nkr54.64 Million | -50.14% |
| 2020 | Nkr109.59 Million | -63.62% |
| 2019 | Nkr301.26 Million | +191.63% |
| 2018 | Nkr103.30 Million | -32.71% |
| 2017 | Nkr153.52 Million | +180.67% |
| 2016 | Nkr54.70 Million | +401.38% |
| 2015 | Nkr10.91 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of PCI Biotech Holding ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $274.95K USD |
| MoneyControl | $274.95K USD |
| MarketWatch | $274.95K USD |
| marketcap.company | $274.95K USD |
| Reuters | $274.95K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more